XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO ® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO ® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To...
CUB Cambodia Approved to Launch Escrow Services, Bolstering Customer Asset Protection
TAIPEI, Jan. 22, 2025 /PRNewswire/ -- Cathay United Bank (CUB), a subsidiary of Cathay Financial Holdings—the largest financial group in Taiwan—has firmly established its presence in Cambodia for over a decade, actively supporting local government's...
Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypes leading to most of the invasive pneumococcal...
